| Hans-Günter Meyer-Thompson | Hepatitiden
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
Schmidbauer C, Schwarz M, Schütz A, Schubert R, Schwanke C, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M.
PLoS One. 2021 Jun 4;16(6):e0252274. doi: 10.1371/journal.pone.0252274. PMID: 34086708; PMCID: PMC8177501.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252274